2022 KLCA-NCC HCC practice guideline

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM. (Clin Mol 2022;28:725-738)

[1]  M. Zheng,et al.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease , 2022, Nature Reviews Nephrology.

[2]  M. Zheng,et al.  Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease , 2022, Journal of clinical and translational hepatology.

[3]  J Zhang,et al.  2019 global NAFLD prevalence - A systematic review and meta-analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  M. Zheng,et al.  Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma , 2021, Chinese medical journal.

[5]  Yu Seol Lee,et al.  A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome , 2021, Hepatology.

[6]  E. Kotsiliti.  Lanifibranor and NASH resolution , 2021, Nature Reviews Gastroenterology & Hepatology.

[7]  N. Lanthier,et al.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.

[8]  B. Neuschwander‐Tetri,et al.  Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. , 2021, The New England journal of medicine.

[9]  K. Cusi,et al.  The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD , 2021, The Journal of clinical endocrinology and metabolism.

[10]  A. Mantovani.  GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss? , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  Moein Ala.  SGLT2 inhibition for cardiovascular diseases, chronic kidney disease and NAFLD. , 2021, Endocrinology.

[12]  Donghee Kim,et al.  Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. , 2021, Journal of hepatology.

[13]  C. Byrne,et al.  Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications , 2021, Diabetes, obesity & metabolism.

[14]  C. Canivet,et al.  Anti-diabetic drugs and NASH: from current options to promising perspectives , 2021, Expert opinion on investigational drugs.

[15]  Hirokazu Takahashi,et al.  Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD , 2021, Hepatology communications.

[16]  B. Finck,et al.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus , 2021, Nature Reviews Endocrinology.

[17]  M. Roden,et al.  The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments , 2021, Nature Reviews Gastroenterology & Hepatology.

[18]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[19]  Jianfang Fu,et al.  Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis , 2021, Frontiers in Endocrinology.

[20]  E. Schiff,et al.  Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial , 2021, Hepatology.

[21]  A. Lonardo,et al.  Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials , 2021, Metabolites.

[22]  M. Zheng,et al.  Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. , 2021, Hepatobiliary surgery and nutrition.

[23]  M. Zheng,et al.  The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF). , 2021, Hepatobiliary surgery and nutrition.

[24]  G. Targher,et al.  Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials , 2020, Metabolites.

[25]  M. Zheng,et al.  Clinical utility of the MAFLD definition. , 2020, Journal of hepatology.

[26]  Gang Cao,et al.  Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. , 2020, Pharmacology & therapeutics.

[27]  Donghee Kim,et al.  Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease , 2020, Clinical and molecular hepatology.

[28]  J. Bosch,et al.  Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. , 2020, Journal of hepatology.

[29]  M. Zheng,et al.  MAFLD and risk of CKD. , 2020, Metabolism: clinical and experimental.

[30]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[31]  F. Tacke,et al.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.

[32]  H. Tilg,et al.  Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals , 2020, Gut.

[33]  V. Wong,et al.  From NAFLD to MAFLD: a “redefining” moment for fatty liver disease , 2020, Chinese medical journal.

[34]  F. Tacke,et al.  Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. , 2020, Journal of hepatology.

[35]  M. Marre,et al.  Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). , 2020, Diabetes & metabolism.

[36]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[37]  T. Therneau,et al.  The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study. , 2019, Journal of hepatology.

[38]  U. Kaul,et al.  New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence , 2019, Cardiovascular Diabetology.

[39]  G. Qin,et al.  Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[40]  R. DeFronzo,et al.  Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes , 2019, Diabetes & vascular disease research.

[41]  W. Kernan,et al.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.

[42]  T. Vilsbøll,et al.  Glucagon-like peptide 1 in health and disease , 2018, Nature Reviews Endocrinology.

[43]  Shahinul Alam,et al.  Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial , 2018, Hepatic medicine : evidence and research.

[44]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[45]  M. Nauck,et al.  Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns , 2018, Trends in Endocrinology & Metabolism.

[46]  A. Lonardo,et al.  Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? , 2018, Journal of hepatology.

[47]  C. Byrne,et al.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus , 2018, Nature Reviews Endocrinology.

[48]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[49]  M. Boemi,et al.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. , 2017, The lancet. Diabetes & endocrinology.

[50]  S. Trattnig,et al.  Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients , 2017, European journal of clinical investigation.

[51]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[52]  P. Schauer,et al.  Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery , 2017, BMC Obesity.

[53]  I. Leclercq,et al.  The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis , 2017, Hepatology communications.

[54]  A. Lonardo,et al.  Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? , 2017, European Respiratory Journal.

[55]  C. McKenzie,et al.  Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. , 2017, World journal of gastroenterology.

[56]  M. Hussain,et al.  Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease , 2016, Pakistan journal of medical sciences.

[57]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[58]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[59]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[60]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[61]  M. Vázquez-Carrera.  Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease , 2016, Trends in Endocrinology & Metabolism.

[62]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[63]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[64]  G. Marchesini,et al.  Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD? , 2016, Journal of hepatology.

[65]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[66]  D. Drucker,et al.  Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors , 2014, Endocrine reviews.

[67]  A. Avogaro,et al.  The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications , 2014, Diabetes Care.

[68]  G. Firneisz.  Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? , 2014, World journal of gastroenterology.

[69]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[70]  H. Patel,et al.  Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects , 2013, Clinical Drug Investigation.

[71]  M. Laville,et al.  Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects , 2013, Diabetes Care.

[72]  B. Goldstein,et al.  Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies , 2013, Diabetes Therapy.

[73]  J. Kirwan,et al.  Management of non-alcoholic fatty liver disease. , 2013, Minerva gastroenterologica e dietologica.

[74]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[75]  B. Staels,et al.  Thiazolidinediones and PPARγ agonists: time for a reassessment , 2012, Trends in Endocrinology & Metabolism.

[76]  C. Benoist,et al.  PPARγ is a major driver of the accumulation and phenotype of adipose-tissue Treg cells , 2012, Nature.

[77]  B. Staels,et al.  DPP-4 inhibitors in the treatment of type 2 diabetes. , 2012, Biochemical pharmacology.

[78]  R. Henry,et al.  SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.

[79]  Y. E. Chen,et al.  Molecular recognition of nitrated fatty acids by PPARγ , 2008, Nature Structural &Molecular Biology.

[80]  P. Korkusuz,et al.  Dipeptidyl peptidase IV (DDP IV) in NASH patients. , 2007, Annals of hepatology.

[81]  G. Jacquemin.  [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[82]  A. Young,et al.  Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.

[83]  B. Staels,et al.  PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD , 2017, Nature Reviews Endocrinology.

[84]  C. Streutker,et al.  GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. , 2013, Endocrinology.

[85]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.